TAMBOCOR

Tambocor falls under the category of antiarrhythmic medications, which work by slowing down the electrical impulses responsible for irregular or abnormal heart rhythms. It is prescribed to manage a heart condition known as arrhythmia, characterized by irregular or abnormal heartbeats.

Consuming foods high in saturated fats can lead to increased blood pressure and cholesterol levels. Similarly, foods rich in sodium can also contribute to elevated blood pressure. Additionally, beverages and foods containing high levels of caffeine may exacerbate arrhythmias.

Medications such as Amoxapine, Arsenic trioxide, and certain antibiotics like clarithromycin, erythromycin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, sparfloxacin, or troleandomycin may interact with other drugs and have potential effects on heart rhythm.

This medication has the potential to alter your heart’s rhythm, leading to conditions like PR, QRS, or QT prolongation. In some cases, it may result in fainting or severe side effects. If your symptoms do not improve or worsen, it is crucial to contact your doctor promptly.

Flecainide is used to restore normal heart rhythm in specific types of arrhythmias (abnormal heart rhythms). However, it may cause dizziness and changes in vision as side effects.

Flecainide carries an FDA Black Box Warning, recommending its use exclusively for life-threatening ventricular arrhythmias, as studies have not demonstrated survival benefits in other scenarios. It is cautioned against for chronic atrial fibrillation due to potential proarrhythmic effects.

Amiodarone (Cordarone, Nexterone, Pacerone) serves as both a sodium channel blocker and a potassium channel blocker. It is considered one of the most effective antiarrhythmic drugs available, with potential effectiveness reaching as high as 75%.

Flecainide is prescribed to prevent or manage irregular heartbeats, including paroxysmal supraventricular tachycardia (PSVT) and paroxysmal atrial fibrillation/flutter (PAF). It is also used to prevent life-threatening sustained ventricular tachycardia (sustained VT).

Rhythmol and Tambocor are generally well tolerated, provided they do not induce proarrhythmia. In young, healthy individuals without underlying heart conditions and a low risk of heart disease, these medications typically result in minimal proarrhythmia.

Many individuals using this medication experience minimal side effects. However, it is essential to inform your doctor immediately if you encounter serious side effects, such as new or worsening symptoms of heart failure, including shortness of breath, swelling in the ankles or feet, unusual fatigue, or sudden weight gain.

Common side effects related to the heart may include fluctuations in heart rate (bradycardia, tachycardia), palpitations, cardiac arrest, heart failure, chest pain, heart attack, and decreased blood pressure (hypotension).

Tambocor may lead to severe side effects, such as rapid or forceful heartbeats, chest fluttering, shortness of breath, and sudden dizziness resembling a near-fainting episode.

Similarly, the product label for flecainide highlights a notable occurrence of central nervous system (CNS) adverse effects, including dizziness (19-30%), visual disturbances (16%), fatigue (8%), and somnolence and insomnia, occurring at a frequency between 1% and 3%.

Flecainide is a prescription antiarrhythmic medication used to treat life-threatening irregular or abnormal heart rhythms. It is also marketed under the brand name Tambocor.

Both drugs are effective for their licensed indications. Your doctor will discuss which medication is the most suitable considering your health circumstances and condition which is being treated.

Flecainide should not be used if you are allergic to it or have a severe heart condition, such as bundle branch block or AV block (unless you have a pacemaker). Additionally, if your heart is unable to pump blood effectively, it is not recommended.

Discontinued. The manufacturer has discontinued this particular form and dosage of Tambocor, making it no longer available.

Common side effects of flecainide may include dizziness, vision problems (blurred vision, difficulty focusing, seeing spots), headaches, nausea, shaking, tiredness, or weakness. If any of these effects persist or worsen, consult your doctor or pharmacist.

Use caution if you have congestive heart failure (severe), heart disease (e.g., cardiomyopathy), or sick sinus syndrome (a type of abnormal heart rhythm) while taking flecainide, as it may exacerbate these conditions.

Peripheral neuropathy (sensory loss) associated with flecainide has been reported in at least 6 cases, typically developing after prolonged use (2 to 10 years). However, symptoms, such as lower-extremity weakness and paresthesias, tend to resolve over 3 to 6 months following discontinuation of flecainide therapy.

Individuals with atrial fibrillation or atrial flutter who use flecainide may have an increased risk of developing specific irregular heart rhythms. It is advisable to discuss the risks associated with flecainide with your doctor.

Flecainide should be used cautiously in individuals with liver problems, unless specifically recommended by a doctor. Monitoring the medication levels in your body may be necessary before any dose adjustments.

Symptoms of an overdose may encompass nausea, vomiting, slow heart rate, fainting, or seizures (convulsions).

In conclusion, combining flecainide and metoprolol therapy enhances the effectiveness of rhythm control in persistent symptomatic atrial fibrillation (AF), improving tolerability, reducing side effects, and promoting better compliance.

Both drugs are effective for their licensed indications. Your doctor will discuss which medication is the most suitable considering your health circumstances and condition which is being treated.

If prescribed flecainide, you may also need to take a beta-blocker or calcium channel blocker to safeguard the lower chambers of the heart (ventricles) from contracting too rapidly.

The single-dose oral loading regimen of flecainide has proven effective in cardioverting recent-onset atrial fibrillation within 2-4 hours, with minimal serious complications, particularly in patients without structural heart disease.

Flecainide significantly decreases various parameters of heart rate variability in both the time and frequency domains, including markers of vagal activity.

Possible side effects of flecainide may encompass dizziness, vision problems (blurred vision, focusing difficulties, spots in vision), shortness of breath, headache, nausea, vomiting, stomach pain, and diarrhea.